Advertisement
Published in:
2013 | OriginalPaper | Chapter
Quantitative Risk/Benefit Assessment: Where Are We?
Author : Christy Chuang-Stein
Published in: Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials
Publisher: Springer New York
Activate our intelligent search to find suitable subject content or patents.
Select sections of text to find matching patents with Artificial Intelligence. powered by
Select sections of text to find additional relevant content using AI-assisted search. powered by
Abstract
Pharmaceutical sponsors use a variety of approaches to make important benefit/risk decisions about their products internally. Benefit/risk assessment is equally important when regulators evaluate a product for marketing approval and payers evaluate it for reimbursement decision. Once a product receives marketing authorization, it is critical to communicate pertinent benefit and risk information to patients and health-care providers. All of the above can be made easier by the use of a common framework. In this paper, we review where we are in benefit/risk assessment. This includes endeavors by academic institutions, regulators, and the pharmaceutical industry. Despite concerns about quantitative benefit/risk assessment expressed by some, we argue that without a way to quantitatively incorporate the relative importance of factors impacting benefit/risk assessment, it will be hard to bring transparent decisions to questions such as “does the benefit of this product outweigh the risk.”